Brokers Issue Forecasts for AEON Biopharma, Inc.’s Q3 2024 Earnings (NASDAQ:AEON)

AEON Biopharma, Inc. (NASDAQ:AEON) – Equities research analysts at HC Wainwright boosted their Q3 2024 earnings per share estimates for AEON Biopharma in a research report issued to clients and investors on Wednesday, August 14th. HC Wainwright analyst D. Tsao now expects that the company will post earnings of ($0.16) per share for the quarter, up from their prior forecast of ($0.22). HC Wainwright currently has a “Buy” rating and a $5.00 price target on the stock. The consensus estimate for AEON Biopharma’s current full-year earnings is ($0.91) per share. HC Wainwright also issued estimates for AEON Biopharma’s Q4 2024 earnings at ($0.18) EPS, FY2024 earnings at ($0.77) EPS, Q1 2025 earnings at ($0.19) EPS, Q2 2025 earnings at ($0.16) EPS, Q3 2025 earnings at ($0.17) EPS, Q4 2025 earnings at ($0.17) EPS, FY2025 earnings at ($0.69) EPS, FY2026 earnings at ($0.70) EPS and FY2027 earnings at ($0.42) EPS.

AEON Biopharma Stock Performance

AEON opened at $1.02 on Friday. AEON Biopharma has a 1-year low of $0.80 and a 1-year high of $17.17. The firm has a 50-day moving average price of $1.46 and a two-hundred day moving average price of $5.23.

Institutional Trading of AEON Biopharma

A hedge fund recently raised its stake in AEON Biopharma stock. Vanguard Group Inc. raised its position in AEON Biopharma, Inc. (NASDAQ:AEON) by 261.8% during the first quarter, according to its most recent 13F filing with the SEC. The fund owned 758,992 shares of the company’s stock after buying an additional 549,207 shares during the period. Vanguard Group Inc. owned about 2.01% of AEON Biopharma worth $8,804,000 as of its most recent filing with the SEC. Institutional investors own 22.78% of the company’s stock.

AEON Biopharma Company Profile

AEON Biopharma, Inc, a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of both chronic and episodic migraine.